J Natl Compr Canc Netw. 2026 Mar 31;24(3.5):CLO26-105. doi: 10.6004/jnccn.2025.7191.
NO ABSTRACT
PMID:41911721 | DOI:10.6004/jnccn.2025.7191
Recent Content
- Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States
- Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly
- Development and multinational validation of a multiple myeloma–specific comorbidity index using real-world cohorts: CAREMM-2108
- Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- CLO26-105: Gut Microbiota and Multiple Myeloma: A Systematic Review of Risk, Prognosis, and Therapeutic Implications
- EU panel backs approval of under-the-skin Sarclisa for myeloma
- Management of hematological toxicities after BCMA-directed CAR-T cell therapy
- Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification
- Risk factors for infections in patients with multiple myeloma: a systematic review and meta-analysis